Expertise in
10
conditions

Jean Reignier

Nantes, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Nantes, FR 

Overview

Jean Reignier practices in Nantes, France. Ms. Reignier is highly rated in 10 conditions, according to our data. Her top areas of expertise are Pneumonia, Acute Respiratory Distress Syndrome (ARDS), Hypothermia, Hospital-Acquired Pneumonia, and Endoscopy.

Her clinical research consists of co-authoring 204 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Nantes, France
Other Locations
Ur, France
Creteil, France
Lille, 59000, France
Clermont-ferrand, France
Common And Rare Kidney Diseases, UMR S 1155, Paris, France
Limoges, France
Poitiers, France
Amiens, 80000, France
Brest, France
Tours, France
INSERM CIC 1402, And CIC 1435, Point A-Pitre All In France, Montauban, France
Montpellier, France
Angers, France
La Roche, 85925, France
Roches, 85025, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Enrollment Status: Recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drug: Levosimendan
Study Phase: Phase 3
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: February 09, 2026
Intervention Type: Procedure
Study Phase: Phase 3
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drug: Hydrocortisone
Study Phase: Phase 3
Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome
Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Other
Study Phase: Not Applicable
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Drugs: Remdesivir, Lopinavir, Ritonavir, Interferon Beta-1A, Hydroxychloroquine, AZD7442
Study Phase: Phase 3
The Arginine Vasopressin aXis as a Potential Therapeutic Target for Posterior REverSible Encephalopathy SyndromE (XPRESSE)
The Arginine Vasopressin aXis as a Potential Therapeutic Target for Posterior REverSible Encephalopathy SyndromE (XPRESSE)
Enrollment Status: Completed
Publish Date: July 22, 2024
Intervention Type: Other, Biological
Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.
Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.
Enrollment Status: Terminated
Publish Date: September 28, 2022
Intervention Type: Other
Study Phase: Not Applicable
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Biological, Other
Study Drug: Cx611
Study Phase: Phase 1/Phase 2
Impact of Rational Control of Fluid Balance in the Intensive Care Unit.IRIHS-REA
Impact of Rational Control of Fluid Balance in the Intensive Care Unit.IRIHS-REA
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

204 Total Publications

Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial.
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial.
Journal: JAMA
Published: October 29, 2025

Frequently Asked Questions about Jean Reignier

Is Jean Reignier a top-rated expert for Pneumonia?

MediFind is an objective health platform that identifies experts based on real-world data. Jean Reignier is classified as an Distinguished expert for Pneumonia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean Reignier participate in research or clinical trials?

Yes. Jean Reignier has published 204 articles and abstracts on conditions like Pneumonia. You can view a list of Jean Reignier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Reignier's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile